Scancell Holdings PLC
Company Profile
Business description
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
Contact
Sanders Road
Unit 202, Bellhouse Building
Oxford Science Park
OxfordOX4 4GD
GBRT: +44 1865582066
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2026
Employees
61
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
stocks
New ASX share added to our best ideas
stocks
Fair value downgraded for ASX heavyweight
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,240.30 | 42.60 | 0.46% |
CAC 40 | 8,060.17 | 93.22 | 1.17% |
DAX 40 | 24,416.71 | 303.09 | 1.26% |
Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
FTSE 100 | 9,457.50 | 11.07 | 0.12% |
HKSE | 27,287.12 | 431.56 | 1.61% |
NASDAQ | 22,755.16 | 95.15 | 0.42% |
Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
S&P 500 | 6,711.20 | 22.74 | 0.34% |
S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |